Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
NCT01429610
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
78
Enrollment
OTHER
Sponsor class
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions
DRUG:
Rituximab+mVPDL
Sponsor
Asan Medical Center